AllAnalyst Report
logoMorningstarDecember 01, 2021

Qiagen N.V.: Qiagen's COVID-19 Tailwinds May Turn Into Headwinds Eventually

Symbols
Sector(s)
Rating
Current Price
Fair Value
Economic Moat
Stewardship
Summary

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

Julie Utterback

Senior Analyst
Julie Utterback is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers life sciences firms in the healthcare industry.Utterback initially joined Morningstar in 2005 as an equity analyst in the healthcare industry. At that time, she covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage on the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until rejoining the equity team in April 2019.Prior to joining Morningstar, Utterback was an equity analyst at State Farm Insurance for several years. She holds a bachelor's degree in finance from the University of Illinois Urbana- Champaign. She also holds the Chartered Financial Analyst® designation.